与人类免疫缺陷病毒1型逆转录酶中K70G和M184V突变相关的新型耐药模式。
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
作者信息
Bradshaw D, Malik S, Booth C, Van Houtte M, Pattery T, Waters A, Ainsworth J, Geretti A M
机构信息
Department of Virology, Royal Free Hospital, Pond Street, London NW3 2QG, United Kingdom.
出版信息
Antimicrob Agents Chemother. 2007 Dec;51(12):4489-91. doi: 10.1128/AAC.00687-07. Epub 2007 Sep 17.
Abstract
We describe an unusual pathway of human immunodeficiency virus type 1 reverse transcriptase resistance during therapy with tenofovir-emtricitabine, characterized initially by the mutations K70E and M184V and later by K70G and M184V, with the two mutations coexisting on the same viral genome. Phenotypic resistance to lamivudine, emtricitabine, abacavir, didanosine, and tenofovir was observed, whereas susceptibility to zidovudine and stavudine was preserved.
摘要
我们描述了在使用替诺福韦-恩曲他滨治疗期间，人类免疫缺陷病毒1型逆转录酶产生耐药性的一种不寻常途径，其最初特征为K70E和M184V突变，随后为K70G和M184V突变，这两种突变共存于同一病毒基因组上。观察到对拉米夫定、恩曲他滨、阿巴卡韦、去羟肌苷和替诺福韦具有表型耐药性，而对齐多夫定和司他夫定仍保持敏感性。
相似文献
1
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
Antimicrob Agents Chemother. 2007 Dec;51(12):4489-91. doi: 10.1128/AAC.00687-07. Epub 2007 Sep 17.
2
In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
Antimicrob Agents Chemother. 2006 Dec;50(12):4087-95. doi: 10.1128/AAC.00816-06. Epub 2006 Sep 18.
3
Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
Antiviral Res. 2007 Sep;75(3):210-8. doi: 10.1016/j.antiviral.2007.03.006. Epub 2007 Apr 4.
4
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Antimicrob Agents Chemother. 2007 Jan;51(1):48-53. doi: 10.1128/AAC.00683-06. Epub 2006 Nov 6.
5
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
AIDS. 1998 May 7;12(7):705-12. doi: 10.1097/00002030-199807000-00006.
6
Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
Antivir Ther. 2007;12(3):335-43.
7
Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
Antivir Ther. 2012;17(6):993-9. doi: 10.3851/IMP2266. Epub 2012 Jul 26.
8
Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways.
Infect Genet Evol. 2007 Sep;7(5):600-3. doi: 10.1016/j.meegid.2007.05.006. Epub 2007 May 13.
9
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
J Virol. 2006 May;80(10):4971-7. doi: 10.1128/JVI.80.10.4971-4977.2006.
10
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):428-36. doi: 10.1097/QAI.0b013e31817bbe93.
引用本文的文献
1
Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.
Viruses. 2021 May 11;13(5):879. doi: 10.3390/v13050879.
2
Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.
J Biol Chem. 2013 Jun 14;288(24):17336-46. doi: 10.1074/jbc.M112.433441. Epub 2013 Apr 18.
3
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.
Antimicrob Agents Chemother. 2012 May;56(5):2305-13. doi: 10.1128/AAC.05487-11. Epub 2012 Feb 13.
4
Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?
Clin Infect Dis. 2011 Dec;53(12):1265-70. doi: 10.1093/cid/cir684. Epub 2011 Oct 5.
5
Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.
Antimicrob Agents Chemother. 2009 Nov;53(11):4869-78. doi: 10.1128/AAC.00592-09. Epub 2009 Aug 31.
6
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.
AIDS Rev. 2008 Apr-Jun;10(2):67-84.
本文引用的文献
1
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Antimicrob Agents Chemother. 2007 Jan;51(1):48-53. doi: 10.1128/AAC.00683-06. Epub 2006 Nov 6.
2
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
HIV Med. 2006 Oct;7(7):442-50. doi: 10.1111/j.1468-1293.2006.00404.x.
3
In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.
Antimicrob Agents Chemother. 2005 Sep;49(9):3930-2. doi: 10.1128/AAC.49.9.3930-3932.2005.
4
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
J Clin Virol. 2005 Mar;32(3):241-4. doi: 10.1016/j.jcv.2004.05.020.
5
Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.
Mol Pharmacol. 1998 Aug;54(2):291-7. doi: 10.1124/mol.54.2.291.
6
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.
Antimicrob Agents Chemother. 1998 Jul;42(7):1620-8. doi: 10.1128/AAC.42.7.1620.
7
Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.
Antimicrob Agents Chemother. 1996 Sep;40(9):2212-6. doi: 10.1128/AAC.40.9.2212.
Zotero 插件